LEXINGTON, Mass., Sept. 11, 2015 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease, today announced that preclinical data regarding the pharmacokinetics and potency of PUR1900, the first inhaled antifungal medication for cystic fibrosis, will be presented at the 2015 North American Cystic Fibrosis Conference. Pulmatrix's chief scientific officer, David L. Hava, Ph.D., will present the data, which show that itraconazole, the drug selected for development as PUR1900, was active and potent in vitro against Aspergillus fumigatus, a pathogen causing pulmonary infection in cystic fibrosis. Pharmacokinetic data also demonstrate that PUR1900 achieved high lung concentrations of itraconazole and low systemic exposure following lung delivery in rats, highlighting the advantages of pulmonary delivery for this compound.
Details of the presentation are as follows:
Event: North American Cystic Fibrosis 2015 Conference
Date: October 8, 2015
Presentation Name: Pharmacokinetics and In Vitro Activity of Antifungal Drugs for Pulmonary Delivery
Time: 11:50 a.m. MST
Location: CDE Hall, North Building, Phoenix Convention Center, Phoenix, Arizona
Link to Abstract: http://onlinelibrary.wiley.com/doi/10.1002/ppul.23297/full - Poster #393
The 29th Annual North American Cystic Fibrosis Conference is a scientific meeting for medical professionals in the field of cystic fibrosis research and care. The conference is sponsored by The Cystic Fibrosis Foundation.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) in partnership with Mylan N.V. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
SOURCE Pulmatrix, Inc.